Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Nat Med. 2020 May;26(5):732-740. doi: 10.1038/s41591-020-0840-5. Epub 2020 Apr 27.
Nat Med. 2020.
PMID: 32341578
Clinical Trial.